drugset / Trial / NCT01184599

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

NCT01184599

Phase 4 Unknown 30 enrolled Kagawa University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.

Timeline

Start
2010-06
Primary completion
2013-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg Oral